Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (2113)	1/28/1998 11:06:00 PM
From: Cosmo Daisey	Respond to of 7041

Bill, I don't need the anominity of e-mail to tell you what I think of you and your repetitive posts that Zonagen is a fraud and a scam. Great work, thanks. Dr. Daisey

To: Bill Wexler who wrote (2113)	1/29/1998 12:17:00 AM
From: Tokyo VD	Respond to of 7041

Bill, I don't believe the e-mails I have received can be considered threats. I do believe that they are annoying. They also serve as a constant reminder that people can be deceived (by their emotions). I believe this deception turns to anger when people begin to see real losses in their stock portfolios. In fact, the sheer volume has been somewhat alarming. I only reposted that message because I found it the most amusing. As for Zonagen, it appears to be a simple case of people getting excited about the "potential" for a new product in an exciting industry. The market for products to cure erectile dysfuntion has enormous potential. To exemplify this point, look at Vivus. It is a real company with real earnings. Zonagen, on the other hand, has alot to prove to warrant the current valuations. It is my opinion that the company has not done a very good job of sharing information. They have provided limited access to clinical data. In my opinion, this data has limited value. Many people in this forum have criticized those who desire to see peer review studies. Unfortunately, that is expected of companies (especially those that planned to file an NDA in JUNE 1997). Vivus published the science and the outcomes from a few of its trials prior to filing its NDA (well before the study in New England Journal of Medicine captured Wall Street's fancy last January). Unfortunately, Zonagen has not done the same. So, we are left waiting for an NDA filing or until the AUA meeting (first week of June in San Diego) for any further data from the Zonagen trials that were initially reported by the company in May/June 1997 (immediately prior to a stock offering). It is rumored that Dr. Irwin Goldstein will present at an ED meeting immediately prior to the AUA. Ironically, Dr. Goldstein was supposed to present trial information at an ED conference organized and hosted by Drs. Padma-Nathan and Shabsigh in Los Angeles (September 1997). This never occured. Instead, Zonagen investigator/consultant, Dr. Raymond Rosen, a psychologist, presented his thoughts about the Zonagen data. Tokyo